AI assistant
Protara Therapeutics, Inc. — Director's Dealing 2026
Jan 21, 2026
34057_dirs_2026-01-21_60ba2644-46be-4844-9725-dd6a72fe40f2.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Protara Therapeutics, Inc. (TARA)
CIK: 0001359931
Period of Report: 2026-01-16
Reporting Person: CONKLING WILLIAM (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2026-01-16 | Common Stock | A | 26000 | — | Acquired | 76000 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2026-01-16 | Stock Option (Right to Buy) | $5.01 | A | 158000 | Acquired | 2036-01-15 | Common Stock (158000) | Direct |
Footnotes
F1: The shares being reported are being issued pursuant to restricted stock unit awards (RSUs), each of which represents a contingent right to receive one share of Issuer's common stock. The RSUs vest in equal one third installments on the first, second and third anniversaries of January 16, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such date.
F2: 25% of the shares vest on the one year anniversary of January 16, 2026 and 1/48th of the shares vest monthly thereafter over the next three years, subject to the Reporting Person's continuous service with the Issuer as of each such date.